Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non- alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced that two scientific abstracts have been selected for poster presentation at the upc ...